Earnings season is now winding down and very little has changed in the
healthcare sector. Hospitals in the U.S. are still being cautious with
their capital spending, while European health systems are pushing back
hard on prices for both devices and drugs. Companies with differentiated
products are doing well (Abbott Labs' (NYSE:ABT) Humira, Edwards Lifesciences' (NYSE:EW) transcatheter heart valve), Intuitive Surgical's (Nasdaq:ISRG) DaVinci surgical robot and tools), but general trends seem more like "muddle through" right now.